Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trifluridine + tipiracil + bevacizumab
- Development stage
- Unknown
- Lead developer
- Taiho Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Trifluridine + tipiracil + bevacizumab is a combination therapy used for the treatment of metastatic colorectal cancer in patients who have previously received other chemotherapy regimens. Trifluridine is a thymidine-based nucleoside analogue that incorporates into DNA, causing dysfunction and cell death. Tipiracil inhibits thymidine phosphorylase, thereby increasing the bioavailability of trifluridine by preventing its breakdown. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis and thus starving tumors of oxygen and nutrients. This combination has demonstrated improved survival outcomes in clinical trials for refractory metastatic colorectal cancer[1][2][5][6][8].
- Brand names
- Lonsurf (trifluridine + tipiracil)Avastin (bevacizumab)
- Other names
- FTD/TPI (trifluridine/tipiracil abbreviation)
02
Targets
VEGFA (Vascular endothelial growth factor A)TYMP (Thymidine phosphorylase)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on Trifluridine + tipiracil + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trifluridine + tipiracil + bevacizumab.